Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

IEX · Q1 2026 Earnings

IDEX Corporation

Reported April 29, 2026

30-second summary

Q1 organic sales grew 5% (vs. ~1% guide) and adjusted EPS of $2.00 beat the $1.73–$1.78 guide by 12–16%, with HST revenue +17% reported (+11% organic) and $988M total IDEX orders (+10% organic), of which HST organic orders grew +17%. Management raised FY26 organic growth to 3–4% (from 1–2%) and FY26 adjusted EPS to $8.35–$8.55 (from $8.15–$8.35), while holding the EBITDA margin band at 26.5–27.0% — a meaningful posture change from Q4's "we are not seeing an inflection" framing. The 2pts organic raise without a margin raise says the savings are funding reinvestment, but the EPS lift confirms the operational leverage is real.

Headline numbers

EPS

Q1 FY2026

$2.00

Revenue

Q1 FY2026

$0.89B

+9.0% YoY

Gross margin

Q1 FY2026

44.9%

Free cash flow

Q1 FY2026

$0.09B

Operating margin

Q1 FY2026

19.4%

Key financials

Q1 FY2026

Metric	Q1 FY2026	YoY	Q4 FY2025	QoQ
Revenue	$0.89B	+9.0%	$0.90B	-1.3%
EPS	$2.00	—	$2.10	-4.8%
Gross margin	44.9%	—	43.1%	+180bps
Operating margin	19.4%	—	20.4%	-100bps
Free cash flow	$0.09B	—	$0.19B	-54.7%

Guidance

IDEX raised full-year 2026 organic growth guidance (1–2% → 3–4%) and EPS guidance ($8.15–$8.35 → $8.35–$8.55) following a strong Q1 beat driven by Health & Science Technologies momentum and robust order intake.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
Adjusted Diluted EPS	Q1 FY2026	$1.73 to $1.78	$2.00	+$0.22 to $0.27 above guide	Beat
Organic Sales Growth	Q1 FY2026	approximately 1%	5%	+4pts above guide	Beat
Adjusted EBITDA Margin	Q1 FY2026	approximately 24.5%	26.0%	+1.5pts above guide	Beat

New guidance

Metric	Period	Guide	YoY
Adjusted Diluted EPS	Q2 FY2026	$2.07 to $2.12	—
Organic Sales Growth	Q2 FY2026	3% to 4%	+3–9% YoY

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Adjusted Diluted EPS	FY2026	$8.15 to $8.35	$8.35 to $8.55	+$0.20 at midpoint (from $8.25 to $8.45)	Raised
Organic Sales Growth	FY2026	1% to 2%	3% to 4%	+2pts range (from 1–2% to 3–4%)	Raised
Effective Tax Rate	FY2026	approximately 24%	Withdrawn — no replacement	—	Withdrawn

Reaffirmed unchanged this quarter: Adjusted EBITDA Margin (26.5% to 27.0%)

Segment KPIs

Q1 FY2026

Segment	Q1 FY2026	YoY
Health & Science Technologies	$0.398B	+17.0%
Fluid & Metering Technologies	$0.302B	+4.0%
Fire & Safety/Diversified Products	$0.188B	+2.0%

Other KPIs

Q1 FY2026

Segment	Q1 FY2026
Organic Sales Growth	5%
Orders (reported)	$988.3 million
Organic Orders Growth	10%
Adjusted EBITDA Margin	26.0%
HST Adjusted EBITDA Margin	26.6%
FMT Adjusted EBITDA Margin	32.7%
FSDP Adjusted EBITDA Margin	29.7%
Free Cash Flow Conversion	58%

Management tone

Q2 2025 policy-whiplash reset → Q3 2025 operational discipline and capital return → Q4 2025 "no inflection" hardline → Q1 2026 inflection conceded, growth-platform thesis validated.

Management conceded the inflection it spent three quarters denying. Q4's headline was a verbatim "we are not seeing an inflection point in activity, and our guidance reflects this reality." This quarter management states they are "encouraged by how our strategies are translating into higher-quality growth" and frame "many of the demand trends in our advantage markets are expected to remain robust well beyond 2026." That is not just a one-quarter beat — it's an extension of the visibility horizon, and the +2pts FY26 organic raise puts dollars behind it. The shift signals the order strength flagged in Q4 is converting to revenue and pipeline visibility on schedule.

Acquired businesses pivot from margin drag to growth engine — and now margin opportunity. In Q2 2025, Mott and Muon were "recalibrated" lower. In Q3 2025, management's frame was "intensively deploying 80-20 in these areas to enhance efficiencies." This quarter Muon, Microlam and Mott are named as specific growth contributors with explicit margin upside still ahead via portfolio pruning within them — "as we take some 80-20 actions...as we start to prune some pieces of the portfolio within those businesses that are dragged on the margin...that will help increase the flow through towards that 40%." The post-deal narrative has fully inverted from "digestion" to "compounding."

The "two-speed economy" framing from Q3 is gone, replaced by broader-based strength — but with nuance. Q3 2025 codified the bifurcation between data-center/HST acceleration and a "much more fragmented" broad economy. This quarter, FMT organic prints +2% with water and mining cited as positive contributors. Management still hedges on FMT — "still seeing or forecasting a growth outlook that's a bit flat" — and FSDP organic remains negative at -1%, so the bifurcation isn't fully resolved, but order trends across all three segments are inflecting more positively than the Q4 framing implied.

Energy exposure flipped from headwind to tailwind, foreshadowing a new bull narrative. Q2 and Q3 2025 consistently called out energy/chemical end-market softness. This quarter introduces behind-the-meter power generation and data center thermal management as emerging secular tailwinds, with management noting "the energy exposure at IDEX at least now has moved more to the green." This is the kind of forward-looking framing that didn't exist in any 2025 print.

Hedging language is materially lighter but still present on macro and short-cycle. Management still describes industrial short-cycle as "mixed" and flagged that "diagnostic businesses...didn't move positive in a uniform way," and tariff policy monitoring remains a stated risk. This isn't an all-clear — it's a conviction shift on the durable platforms while preserving caution on the parts of the business genuinely still cyclical.

Recurring themes management leaned on this quarter:

HST backlog expansion and multi-year visibility into space/defense and semiconductor markets80-20 methodology evolving from margin tool to growth platform—extending across acquired business integrationData center thermal management and behind-the-meter power generation as emerging secular tailwindsAcquired businesses (Muon, Microlam, Mott) as growth engines with margin expansion runway via portfolio pruningFire and safety returning to normal spending levels in Europe after temporary diversionM&A integration success in mission-critical markets validating future acquisition strategy

Risks management surfaced:

Geopolitical uncertainty creating macro headwinds and delaying industrial inflectionChina market exposure and NIH funding pressures continuing to weigh on life sciencesChemical end market softness in FMT offsetting water platform strengthShort-cycle diagnostic businesses not yet moving in uniform direction, suggesting incomplete recoveryTariff policy volatility requiring ongoing monitoring and potential price action responses

Answers to last quarter's watch list

Does the Q2 sequential ramp materialize as guided? Q1 organic sales of 5% materially exceeded the ~1% guide, and Q2 FY26 organic guide of 3–4% is incremental to that beat. The Q2 EPS guide of $2.07–$2.12 sequentially +$0.07–$0.12 from Q1 actual of $2.00 is consistent with the more pronounced earnings step-up management telegraphed.

Resolved positively

HST organic growth post-Mott anniversary, clean. HST organic sales grew +11% (reported +17%) — a clean post-anniversary print with the updated FY26 high-single-digit HST segment guide consistent with this pace. Management cites Muon, Microlam, Mott and data center applications as drivers, with HST organic orders +17% reinforcing visibility into 2027.

Resolved positively

Q1 organic orders growth. Total IDEX organic orders grew 10% on $988.3M reported — well above the "low-single-digits" failure threshold, led by HST organic orders +17% and FMT organic orders +9%, with FSDP organic orders -4%. The "no inflection" guide is now confirmed conservative; FY26 organic raised to 3–4% in direct response.

Resolved positively

FSDP YoY trajectory. FSDP organic was -1% in Q1, continuing the organic decline streak (reported +2% reflects FX/acquisition contribution). This is in line with the prior "down" FY26 segment framing, though Fire & Safety strength was offset by Dispensing tough comps.

Continue monitoring

Whether the FY26 EBITDA margin guide gets revised in either direction at Q1. Reaffirmed unchanged at 26.5–27.0% despite the +2pts organic raise. Q1 printed 26.0% vs. ~24.5% guide. The hold implies either continued reinvestment of upside or H2 conservatism — not a margin ceiling. Status: Resolved (held)

Capital deployment cadence. Q1 buybacks of $76M and dividends of $53M; management committed to maintaining the $76M/quarter buyback pace through 2026. FCF of $86M (58% conversion) is seasonally light.

Resolved positively

What to watch into next quarter

Does HST sustain double-digit organic growth in Q2? A second post-anniversary print at or above the +11% Q1 organic level — combined with the +17% HST organic orders backlog build — would push the updated high-single-digit HST FY26 segment guide to look conservative, putting further upside on the FY26 EPS band.

FMT and FSDP organic trajectory vs. the updated "flattish" FY26 segment guide. Q1 FMT organic of +2% modestly exceeded prior "flat-to-slightly-down" framing, while FSDP organic at -1% remained in line with the prior "down" framing. A second confirmation in Q2 that FMT is running above flat and FSDP is stabilizing would set up a further FY26 organic raise.

Q2 organic orders growth vs. Q1's +10%. Sustained double-digit organic orders confirms the durability of the order surge. Deceleration toward mid-single-digits would suggest Q4/Q1 was a backlog catch-up rather than a sustained demand inflection.

EBITDA margin trajectory toward the 26.5–27.0% FY band. Q1 at 26.0% vs. ~24.5% guide suggests significant upside available; whether management lets that flow through to a margin guide raise at Q2, or absorbs it into growth reinvestment, signals the operating-leverage thesis going into 2027.

Whether the withdrawn FY26 effective tax rate guide gets restated. Last quarter's ~24% guide is absent this print with no replacement; clarification at Q2 is the cleanup signal.

Buyback pace sustained at $76M/quarter. Management committed to that cadence for the balance of 2026; sustaining it alongside any bolt-on M&A confirms the "balanced capital deployment" framework remains intact.

Sources

IDEX Q1 FY2026 press release / 8-K exhibit 99.1: https://www.sec.gov/Archives/edgar/data/832101/000083210126000007/iex-20260331xex991.htm

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.